Two Sigma Advisers LP Purchases Shares of 17,800 MaxCyte, Inc. (NASDAQ:MXCT)

Two Sigma Advisers LP acquired a new stake in MaxCyte, Inc. (NASDAQ:MXCT) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 17,800 shares of the company’s stock, valued at approximately $74,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. BNP Paribas Financial Markets bought a new position in shares of MaxCyte during the fourth quarter valued at $56,000. Deutsche Bank AG increased its position in shares of MaxCyte by 65.0% during the 4th quarter. Deutsche Bank AG now owns 98,436 shares of the company’s stock worth $409,000 after purchasing an additional 38,782 shares in the last quarter. Hsbc Holdings PLC lifted its holdings in MaxCyte by 51.4% during the 4th quarter. Hsbc Holdings PLC now owns 48,791 shares of the company’s stock valued at $199,000 after purchasing an additional 16,554 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in MaxCyte by 47.9% during the 4th quarter. Renaissance Technologies LLC now owns 281,200 shares of the company’s stock valued at $1,170,000 after purchasing an additional 91,100 shares during the last quarter. Finally, Rice Hall James & Associates LLC acquired a new position in MaxCyte in the fourth quarter valued at about $1,098,000. 68.81% of the stock is owned by institutional investors.

MaxCyte Price Performance

Shares of NASDAQ MXCT opened at $2.15 on Monday. MaxCyte, Inc. has a 12-month low of $2.10 and a 12-month high of $5.26. The firm’s 50-day simple moving average is $2.48 and its 200 day simple moving average is $3.44. The company has a market cap of $228.59 million, a price-to-earnings ratio of -6.32 and a beta of 1.27.

MaxCyte (NASDAQ:MXCT) last announced its earnings results on Wednesday, May 7th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. The company had revenue of $10.39 million during the quarter, compared to the consensus estimate of $9.05 million. On average, equities analysts expect that MaxCyte, Inc. will post -0.42 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on MXCT shares. BTIG Research set a $6.00 price objective on shares of MaxCyte and gave the stock a “buy” rating in a report on Wednesday, March 12th. Stifel Nicolaus decreased their price target on MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, March 12th. Finally, Wall Street Zen upgraded MaxCyte from a “sell” rating to a “hold” rating in a research report on Sunday.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.